Outlook

2008 Financial outlook

UCB expects 2008 to again be a year of progress in the execution of UCB's strategy and of substantial investment in the company's future growth.

Revenue is expected to decrease to approximately EUR3.4 billion due, in substantial part, to the patent expiry of Zyrtec® and the expected start of generic competition to Keppra® in the USA along with further expected currency deterioration. Notwithstanding incremental marketing & selling expenses in connection with product launches and pre-launch activities, operating expenses should be slightly lower as a result of the continued cost containment efforts.

Recurring EBITDA for the full year 2008 is expected to reach approximately EUR650 million.

Net Profit is expected to exceed EUR100 million in 2008.

Execution Phase: 2007 - 2010

A positive challenge to be mastered

• Patent / exclusivity expirations of Zyrtec® (2007) and Keppra® (Nov.08 / Sept.10)
• Two major product launches continue in the USA: Neupro® and Xyzal®
• Deliver synergies of €380 million p.a. as of 2010 through successful integration of Schwarz Pharma
• Prepare for potential launch of up to four products in seven indications
• Continuous investment into R&D to strengthen pipeline and prepare breakthrough